By Tess Stynes
Shire PLC said Tuesday that it has offered to acquire Baxalta
Inc. in a stock deal valued at roughly $30.6 billion, in a
combination what would create a leader in treatments for rare
diseases.
Under the proposed deal, Baxalta holders would receive 0.1687
Shire American depositary share for each Baxalta share held,
implying a value of $45.23 per Baxalta share and a premium of 36%
based on Monday's closing prices.
Baxalta shares rose 27% to $42.10 in recent premarket trading,
while Shire's ADRs were halted.
A Baxalta spokesman wasn't immediately available to comment.
The offer comes just more than a month after Baxalta, which
sells treatments for rare bleeding disorders and immune
deficiencies, completed its spinoff from Baxter International Inc.
Baxter remains Baxalta's biggest shareholder, with a stake of about
24%, according to FactSet.
In 2014, Baxalta had net sales of $6 billion and net income from
continuing operations of $1.2 billion.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires